The evolution of chemotherapeutic agents for the treatment of pediatric musculoskeletal malignancies.
The incorporation of antineoplastic agents in the treatment of pediatric musculoskeletal malignancies and their impact in the management and outcome of patients with these types of malignancies are briefly reviewed. The role of chemotherapy in the management of these tumors with special emphasis on osteosarcoma, Ewing's sarcoma family of tumors, and rhabdomyosarcoma and undifferentiated sarcomas is discussed. Also included are complications and side effects of the antineoplastic agents.
Velez-Yanguas
M C
MC
Department of Pediatric Hematology/Oncology, Louisiana State University Medical Center, New Orleans, Louisiana, USA.
Warrier
R P
RP
D000970:Antineoplastic Agents / Q000009:adverse effects; D001859:Bone Neoplasms / Q000188:drug therapy*; D002648:Child; D006801:Humans; D019042:Muscle Neoplasms / Q000188:drug therapy*; D012516:Osteosarcoma / Q000188:drug therapy; D012208:Rhabdomyosarcoma / Q000188:drug therapy; D012509:Sarcoma / Q000188:drug therapy; D012512:Sarcoma, Ewing / Q000188:drug therapy
D000970:Antineoplastic Agents